Why Asuragen Chooses Seraseq® ctDNA v2
Asuragen relies on SeraCare’s liquid biopsy products to help streamline sensitive assays and workflows in order to produce high-quality results. Associate Director of Bioinformatics at Asuragen, Brian Haynes, PhD, talks about the importance of high-quality, patient-like reference materials and LOD experiments.
Sandi Deans, UK NEQAS, Discusses the Need for Patient-like Materials
With medical laboratory standards being more closely scrutinized, UK NEQAS turns to SeraCare to aide in their awareness of sensitivity, specificity, and accuracy in limit of detection.
MD Anderson Cancer Center
Reference Materials Prove Instrumental for MD Anderson Cancer Center Lab
SeraCare’s reference materials give Jawad Manekia, PhD, supervisor of a molecular diagnostics laboratory at MD Anderson Cancer Center, the confidence he needs to be able to report that an assay passes quality control.
Target the Tumor Mutational Burden and Pursue Harmonization
Friends aims to better understand the impact of assay variation on clinical outcomes, align standards, and define best practices for TMB assessment. Listen as Dr. Mark Stewart discusses the role of the tumor mutational burden (TMB) in cancer research and the need for harmonization throughout the process.